Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Total Therapy 2 examined the clinical benefit of adding thalidomide up-front to a tandem transplant regimen for newly diagnosed patients with multiple myeloma. When initially reported with a median follow-up of 42 months, complete response rate and event-free survival were superior among the 323 pat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Barlogie, Bart, Pineda-Roman, Mauricio, van Rhee, Frits, Haessler, Jeff, Anaissie, Elias, Hollmig, Klaus, Alsayed, Yazan, Waheed, Sarah, Petty, Nathan, Epstein, Joshua, Shaughnessy, John D., Tricot, Guido, Zangari, Maurizio, Zeldis, Jerome, Barer, Sol, Crowley, John
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2008
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2569166/
https://ncbi.nlm.nih.gov/pubmed/18492953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-03-145235
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares